|
FLAMEL TECH SA AD, (FLML) Stock Research Free Stock Rating
|
|
| |
| Company Profile |
| |
|
Flamel Technologies S.A., a biopharmaceutical company, engages in the development and commercialization of controlled-release therapeutic products based on its proprietary polymer-based technologies. The companys technology, Micropump, is a multiparticulate technology for oral administration of small molecule drugs with applications in controlled-release, tastemasking, and bioavailability development. Micropump technology has various other features, including a high loading ratio of active ingredient to its polymer coating, thus enabling for conventional size tablets or capsules. Its primary products based on its Micropump technology comprise Genvir, a controlled-release acyclovir for the treatment of genital herpes; Metformin XL, a controlled-release form of Metformin for the treatment of type II diabetes; and Asacard, a controlled-release formulation of aspirin for the treatment of cardiovascular disease. The companys technology also includes Medusa, a nano-particulate technology that delivers therapeutic proteins, peptides, and small molecules. This technology permits the controlled-release of proteins without the denaturation or other effects on such proteins of various other delivery systems. Its application for Medusa technology is Basulin, which is long-acting insulin for the treatment of diabetes. In addition, the company develops a patented biomaterial, ColCys. ColCys has applications in soft tissue surgical adhesives and the prevention of post-surgical adhesions. The company has operations primarily in France and North America. Flamel has partnerships with Merck & Co., Inc.; GlaxoSmithKline plc; Corning, Inc.; and TAP Pharmaceutical Products, Inc. The company was founded by Gerard Soula in 1990. Flamel Technologies is headquartered in Venissieux, France.
|
|
